Ponatinib
| CAS No. | 943319-70-8 |
|---|---|
| MDL No. | MFCD17215203 |
| MF | C29H27F3N6O |
| MW | 532.60 |
| InChI Key | PHXJVRSECIGDHY-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Ponatinib is a benzamide formed by the condensation of the carboxy group of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzoic acid with the anilino group of 4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)aniline. It is a multi-target tyrosine kinase inhibitor that targets ABL, SRC, FGFR, and others, designed to overcome imatinib resistance, particularly due to the ABL(T315I) mutation. It functions as an antineoplastic agent and tyrosine kinase inhibitor. Ponatinib is a N-methylpiperazine, a member of benzamides, acetylenic compounds, imidazopyridazines, and (trifluoromethyl)benzenes. It is the conjugate base of ponatinib(1+).
| CAS No. | 943319-70-8 |
|---|---|
| Product Name | Ponatinib |
Biological Targets
ABL1·BCR
Associated Conditions
acute myeloid leukemia·myeloid leukemia·lung adenocarcinoma·myelodysplastic syndrome·thyroid neoplasm·
* The information provided here is compiled from public sources and is for reference only.
